For questions regarding claiming CME Credit, please refer to our FAQ section.


Novel Therapeutic Pathways in the Secondary Prevention  of Atherothrombotic Events in AMI

Program Overview:

Specific populations may be at particular risk for either, and the issues of appropriate antiplatelet regimens for various patients remain a concern. This webcast focuses on chronic antiplatelet therapy in high-risk patients, especially post-MI patients or those with PAD, and in particular the use of protease-activated receptor antagonists (PRA-1 antagonists).


Click Here to access this CME Program   
Release Date:
June 9th, 2015

Expiration Date:
December 9th, 2015 

Estimated Time:
1 hour    
 
MATRIX and REGULATE PCI CME Webcast

Program Overview:

The MATRIX and REGULATE-PCI trials examine 2 of the major bleeding avoidance strategies in patients with acute coronary syndrome (ACS): access-site location and choice of antithrombin agent.This webcast will include data presentation, panel discussion, and audience question and answer opportunities.


Click Here to access this CME Program   
Release Date:
June 8th, 2015

Expiration Date:
December 8th, 2015 

Estimated Time:
1 hour    


PEGASUS, TOTAL and DANAMI3-PRIMULTI

Program Overview:

Patients with STEMI undergoing primary PCI continue to have worse outcomes and higher mortality, bleeding, stent thrombosis, and secondary cardiovascular events. Patterns and controversies unique to primary PCI for STEMI, such as whether radial access benefits patients and what the roles should be for complete revascularization and thrombus aspiration, are evolving. Three trials presented at ACC 2015, combining over 30,000 patients, provide insight into some of these issues. The TOTAL study addresses routine thrombus aspiration, while DANAMI3-PRIMULTI looks at multivessel revascularization and delayed stenting. New information on long-term use of dual antiplatelet therapy comes from PEGASUS-TIMI 54, which evaluated the use of ticagrelor with aspirin for secondary prevention in high-risk patients 1 to 3 years after MI. This webcast will summarize the data, answer audience questions, and provide context through panel discussion on the TOTAL, PEGASUS-TIMI 54, and DANAMI3-PRIMULTI studies.


Click Here to access this CME Program   
Release Date:
June 8th, 2015

Expiration Date:
December 8th, 2015 

Estimated Time:
1 hour    
           
 
Post-AHA 2014 Webcast

Program Overview:

Questions surrounding dual antiplatelet therapy (DAPT) may be answered with trials presented at AHA 2014. Discontinuing DAPT at 6 months with second-generation DES was examined in the ISAR-SAFE and Italic trials. Continuing DAPT up to 30 months wass examined with the anticipated DAPT Study which randomized 9,000 patients to DAPT or aspirin and placebo after 12 months. Following the data presentation, a panel discussion with audience questions will put the recent findings from ISAR-SAFE, Italic, and DAPT studies into context of existing DAPT practices.


Click Here to access this CME Program   
Release Date:
January 21st, 2015

Expiration Date:
July 21st, 2015 

Estimated Time:
1 hour    


Post-TCT Webcast: Refining TAVR Therapies

Program Overview:

Long-term valve durability, stroke complications, and costs remain important considerations when treating patients with transcatheter aortic valve replacement (TAVR) for aortic stenosis. Currently, Medicare reimbursement in the United States is limited to transfemoral TAVR based on cost-effectiveness data. Also, the risk of stroke persists, with the STS/ACC TVT Registry reporting a 30-day stroke rate of 2.8% in general practice. In this live webcast, four internationally renowned experts will discuss important trial data presented at TCT 2014, which will further illuminate the challenges of stroke, cost, and durability associated with TAVR.

Click Here to access this CME Program   
Release Date:
January 21st, 2015

Expiration Date:
July 21st, 2015 

Estimated Time:
1 hour    

Post-TCT 2014 Webcast: New Coronary Devices and Approaches – ABSORB, DKCRUSH, and RIBS-IV

Program Overview:

Best practices in treating bifurcations and drug-eluting stent restenosis are constantly evolving for PCI. Recent trials presented at TCT 2014 illuminate these changes as technology evolves. DES restenosis is less common than with BMS but still occurs at estimates of 3%-10% for second-generation DES. Currently, limited data exist to illustrate differences in outcomes between treatment with angioplasty using a plain balloon or paclitaxel-eluting balloon or implanting a second DES. The RIBS-IV study compared outcomes of drug-eluting stents with those of paclitaxel-eluting balloons for treating DES restenosis.

Provisional stenting is the recommended practice for treating bifurcation lesions at present. The role of imaging and physiologic measurement practices have yet to be determined for side branch lesion assessment. The DKCRUSH trial examines the role of FFR for side branch assessment.

Bioresorbable vascular scaffolds are called the “next revolution” in stenting for PCI. However, long-term outcomes data and comparisons to current stents have been lacking. ABSORB II reports the 1-year outcomes for the Absorb bioresorbable scaffold (Abbott Vascular) compared with those of an everolimus-eluting stent.  


Click Here to access this CME Program    
Release Date:
January 21st, 2015

Expiration Date:
July 21st, 2015 

Estimated Time:
1 hour